These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19456985)

  • 1. Gemcitabine and capecitabine chemotherapy in Japanese patients with immunotherapy-resistant renal cell carcinoma.
    Soga N; Yamada Y; Nishikawa K; Hasegawa Y; Kise H; Arima K; Sugimura Y
    Int J Urol; 2009 Jun; 16(6):576-9. PubMed ID: 19456985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
    Tannir NM; Thall PF; Ng CS; Wang X; Wooten L; Siefker-Radtke A; Mathew P; Pagliaro L; Wood C; Jonasch E
    J Urol; 2008 Sep; 180(3):867-72; discussion 872. PubMed ID: 18635226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
    Bellmunt J; Suarez C; Gallardo E; Rodon J; Pons F; Bonfill T; Beltran M; Moya I; Galtes S; Albanell J; Carles J
    Oncologist; 2014 Sep; 19(9):917-8. PubMed ID: 25142843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma.
    Waters JS; Moss C; Pyle L; James M; Hackett S; A'hern R; Gore M; Eisen T
    Br J Cancer; 2004 Nov; 91(10):1763-8. PubMed ID: 15505625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma.
    Wenzel C; Locker GJ; Bartsch R; Pluschnig U; Mader R; Hussian D; Kramer G; Marberger M; Lintner C; Rauchenwald M; Zielinski CC; Steger GG
    Anticancer Drugs; 2003 Nov; 14(10):779-84. PubMed ID: 14597871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy.
    Petrioli R; Paolelli L; Francini E; Marsili S; Pascucci A; Sciandivasci A; de Rubertis G; Barbanti G; Manganelli A; Salvestrini F; Francini G
    Anticancer Drugs; 2007 Aug; 18(7):817-20. PubMed ID: 17581304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.
    Rini BI; Weinberg V; Small EJ
    Cancer; 2005 Feb; 103(3):553-8. PubMed ID: 15612026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.
    Van Veldhuizen PJ; Hussey M; Lara PN; Mack PC; Gandour-Edwards R; Clark JI; Lange MK; Crawford DE
    Am J Clin Oncol; 2009 Oct; 32(5):453-9. PubMed ID: 19487915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.
    Sperone P; Ferrero A; Daffara F; Priola A; Zaggia B; Volante M; Santini D; Vincenzi B; Badalamenti G; Intrivici C; Del Buono S; De Francia S; Kalomirakis E; Ratti R; Angeli A; Dogliotti L; Papotti M; Terzolo M; Berruti A
    Endocr Relat Cancer; 2010 Jun; 17(2):445-53. PubMed ID: 20410174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
    Amato RJ; Khan M
    Cancer Chemother Pharmacol; 2008 May; 61(6):1069-73. PubMed ID: 17701037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
    Boeck S; Wilkowski R; Bruns CJ; Issels RD; Schulz C; Moosmann N; Laessig D; Haas M; Golf A; Heinemann V
    Oncology; 2007; 73(3-4):221-7. PubMed ID: 18424886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
    Bellmunt J; Trigo JM; Calvo E; Carles J; Pérez-Gracia JL; Rubió J; Virizuela JA; López R; Lázaro M; Albanell J
    Lancet Oncol; 2010 Apr; 11(4):350-7. PubMed ID: 20163987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
    Tagawa ST; Milowsky MI; Jeske S; Mazumdar M; Kung S; Sung M; Lehrer D; Matulich D; Selzer J; Wright JJ; Nanus DM
    Am J Clin Oncol; 2011 Oct; 34(5):443-8. PubMed ID: 20881475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
    Kim SH; Shin SJ; Kim SY; Lee SH; Park YS; Park SH; Lee KH; Kim TW; Hong YS; Ahn JB
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):91-7. PubMed ID: 21607556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma.
    Tsimafeyeu I; Demidov L; Kharkevich G; Petenko N; Galchenko V; Sinelnikov I; Naidzionak U
    Am J Clin Oncol; 2012 Jun; 35(3):251-4. PubMed ID: 21358295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A pilot clinical trial of gemcitabine and capecitabine chemotherapy for the treatment of advanced renal cell carcinoma failing immunotherapy].
    Kobayashi M; Nakano K; Ikeda H; Nukui A; Suzuki K; Sugaya Y; Yuzawa M; Morita T
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):277-9. PubMed ID: 18281765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.
    Stadler WM; Halabi S; Rini B; Ernstoff MS; Davila E; Picus J; Barrier R; Small EJ;
    Cancer; 2006 Sep; 107(6):1273-9. PubMed ID: 16909426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.
    Lee JL; Kim SC; Kim JH; Lee SS; Kim TW; Park DH; Seo DW; Lee SK; Kim MH; Kim JH; Park JH; Shin SH; Han DJ
    Surgery; 2012 Nov; 152(5):851-62. PubMed ID: 22682078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
    Wenzel C; Locker GJ; Schmidinger M; Mader R; Kramer G; Marberger M; Rauchenwald M; Zielinski CC; Steger GG
    Am J Kidney Dis; 2002 Jan; 39(1):48-54. PubMed ID: 11774101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.